1. Home
  2. IKT vs RC Comparison

IKT vs RC Comparison

Compare IKT & RC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.65

Market Cap

274.9M

Sector

Health Care

ML Signal

HOLD

Logo Ready Capital Corproation

RC

Ready Capital Corproation

HOLD

Current Price

$1.17

Market Cap

272.6M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
IKT
RC
Founded
2008
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
274.9M
272.6M
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
IKT
RC
Price
$1.65
$1.17
Analyst Decision
Strong Buy
Hold
Analyst Count
10
7
Target Price
★ $5.55
$1.50
AVG Volume (30 Days)
559.3K
★ 1.6M
Earning Date
11-13-2026
11-05-2026
Dividend Yield
N/A
★ 3.64%
EPS Growth
★ 57.76
45.25
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$33.33
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.33
$1.06
52 Week High
$2.61
$3.24

Technical Indicators

Market Signals
Indicator
IKT
RC
Relative Strength Index (RSI) 25.79 36.79
Support Level $1.59 $1.08
Resistance Level $1.74 $1.88
Average True Range (ATR) 0.11 0.08
MACD -0.03 0.00
Stochastic Oscillator 4.85 24.14

Price Performance

Historical Comparison
IKT
RC

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

About RC Ready Capital Corproation

Ready Capital Corp is a real estate finance company that originates, acquires, finances, and services LMM loans, SBA loans, construction loans, USDA loans and, to a lesser extent, MBS collateralized mainly by LMM loans or other real estate-related investments. Its loans are used by businesses to purchase real estate used in their operations or by investors seeking to acquire multi-family, office, retail, mixed use or warehouse properties. It operates through two segments: LMM Commercial Real Estate, which originates LMM loans across the life-cycle of an LMM property including construction, bridge, stabilized and agency loan channels, and Small Business Lending, which acquires, originates and services owner-occupied loans guaranteed by the SBA and also originates and services USDA loans.

Share on Social Networks: